Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy.
Sona Mitra, Abhishek Deshmukh, Rajesh Sachdeva...
https://pubmed.ncbi.nlm.nih.gov/21747278/Actively Recruiting
Led by Xuanwu Hospital, Beijing · Updated on 2025-03-25
200
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating whether combining Probucol with statin therapy can better reduce vascular event risks and improve atherosclerosis outcomes in adults who have had an ischemic stroke and confirmed atherosclerosis. This prospective, open-label study investigates if adding Probucol to guideline-recommended statin therapy decreases plaque burden and lowers the chance of cardiovascular and cerebrovascular events compared to statins alone. Participants will either receive standard lipid-lowering therapy based on current guidelines, which may include statins, ezetimibe, or PCSK9 inhibitors, or the same therapy combined with Probucol 0.5 grams twice daily. The study will include at least 100 participants in each group and follow them over a period of three years to monitor effects on atherosclerosis progression and vascular outcomes. During the study, participants will attend regular follow-up visits to assess changes in plaque burden and atherosclerotic features through imaging studies and blood tests. Researchers will measure lipid levels and biomarkers such as LDL-C, Ox-LDL, and Lpa, while monitoring for cardiovascular events and safety outcomes. The primary measurement is the change in plaque burden from baseline to 12 months, with additional assessments at 1, 12, and 24 months to evaluate functional outcomes and vascular event occurrence.
CONDITIONS
Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke
X
Xin Ma, Doctor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Xuanwu Hospital, Beijing
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants receive either conventional lipid-lowering therapy following clinical guidelines or a combination of conventional therapy with Probucol 0.5g twice daily to reduce atherosclerotic plaque burden and improve cardiovascular outcomes.
Visits as per treatment monitoring schedule
Duration - Up to 12 additional months after treatment
Participants are monitored for cardiovascular events, stroke recurrence, and functional outcomes after treatment ends.
Visits at 12 months and 24 months follow-up
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sona Mitra, Abhishek Deshmukh, Rajesh Sachdeva...
https://pubmed.ncbi.nlm.nih.gov/21747278/Qi Kong, Xin Ma, Chen Wang...
https://pubmed.ncbi.nlm.nih.gov/32336234/Safi U Khan, Siva H Yedlapati, Ahmad N Lone...
https://pubmed.ncbi.nlm.nih.gov/35508321/Salim S Virani, L Kristin Newby, Suzanne V Arnold...
https://pubmed.ncbi.nlm.nih.gov/37471501/M Naruszewicz, E Selinger, R Dufour...
https://pubmed.ncbi.nlm.nih.gov/1435295/Dawn O Kleindorfer, Amytis Towfighi, Seemant Chaturvedi...
https://pubmed.ncbi.nlm.nih.gov/34024117/Peter Libby
https://pubmed.ncbi.nlm.nih.gov/33883728/Freddy Duarte Lau, Robert P Giugliano
https://pubmed.ncbi.nlm.nih.gov/35583875/Hidenori Arai, Hideaki Bujo, Daisaku Masuda...
https://pubmed.ncbi.nlm.nih.gov/33867420/Bing Bing Zhu, Hao Wang, Yang Feng Chi...
https://pubmed.ncbi.nlm.nih.gov/29115480/Xuanwu Hospital, Beijing
Lead Sponsor